ArticleDigestive diseases and sciences2026
SOX4 Knockdown Represses Pancreatic Acinar Cells Ferroptosis in Acute Pancreatitis Through Reducing LPCAT3 Expression.
Article in Digestive diseases and sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAcute pancreatitis (AP) is a severe inflammatory disorder characterized by pancreatic acinar cell injury, with ferroptosis, a form of iron-dependent lipid peroxidation-driven cell death, playing a key role in disease progression. However, the molecular mechanisms of ferroptosis regulation in AP remain unclear. SRY-related HMG-box 4 (SOX4) has been implicated in ferroptosis regulation in other pathological conditions, but its role in AP has not been fully elucidated.
methodsIn this study, I used caerulein (Cae)-induced primary mouse pancreatic acinar cells as an AP model in vitro, with ferroptosis inhibitor ferrostatin-1 (Fer-1) treatment to assess ferroptotic involvement. I further manipulated SOX4 expression via shRNA-mediated knockdown, and its downstream effects on ferroptosis-related markers were evaluated by qPCR, WB, and lipid peroxidation assays. I also performed chromatin immunoprecipitation (ChIP) and dual-luciferase reporter assays to determine whether SOX4 directly regulates Lysophosphatidylcholine Acyltransferase 3 (LPCAT3), a key enzyme in ferroptosis modulation.
resultsI found that SOX4 expression was upregulated in Cae-induced AP cells, correlating with increased ferroptotic markers, including elevated lipid ROS, MDA, and Fe
conclusionThis study identifies SOX4 as a key regulator of ferroptosis in AP through transcriptional upregulation of LPCAT3. Targeting the SOX4-LPCAT3 axis may represent an advanced therapeutic strategy for mitigating pancreatic injury in AP.
Indexed as
Identifiers
42217103What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.